Log In

 
Company : Ferring Pharmaceuticals 
Monday, December 19, 2016 7:28PM IST (1:58PM GMT)
 
(BW)(FERRING-PHARMACEUTICALS)
Ferring and IMAB Sign Licensing Agreement Granting IMAB Exclusive Rights in Asia to Olamkicept for the Treatment of Autoimmune Disease
Saint-Prex, Switzerland

Ferring Pharmaceuticals and IMAB today announced that they have signed a licensing agreement which grants IMAB exclusive rights to olamkicept (pINN) in Asia.

 

Olamkicept is a new recombinant protein inhibitor of the interleukin-6 pathway. Interleukin-6 is associated with numerous inflammatory conditions such as inflammatory bowel diseases (IBD) and rheumatoid arthritis.

 

The agreement provides IMAB with a Phase 2 ready asset with differentiated product profile. Under the terms of the arrangement, IMAB will fund further product development in exchange for an exclusive license in Asia with an option for worldwide use, with the goal of realizing the potential of olamkicept as a biomarker-guided and differentiated interleukin-6 blocker to treat autoimmune disease.

 

“We are very pleased to acquire the opportunity to further advance olamkicept and build on Ferring’s encouraging Phase 1 results in volunteers and in patients,” said Jingwu Zang, President and CEO of IMAB. “This agreement will accelerate IMAB’s mission to develop impactful therapies for autoimmune disease.”

 

“IMAB has a strong network of researchers and physicians in the autoimmune area in China and a willingness to develop our drug further in Asia and around the world,” said Alan Harris, Senior Vice President, R&D, Ferring Pharmaceuticals. “We are pleased to partner with IMAB in progressing our drug in this important therapeutic area with many unmet medical needs.”

 

Ends

 

About Olamkicept

 

Olamkicept (pINN) is a recombinant Interleukin-6 (IL-6) soluble receptor antagonist based on an innovation by the Kiel-based German biotech company Conaris. IL-6 is a key cytokine in the pathogenesis of autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis. Olamkicept is a selective inhibitor of the IL-6 inflammatory pathway expected to be efficacious in disease treatment without affecting the beneficial effects of IL-6 for instance in the acute immune response to infection. The safety of olamkicept has been demonstrated in a phase 1 program.

 

About Ferring Pharmaceuticals

 

Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.

 

About IMAB

 

I-MAB is a Shanghai-based biotech company (天境生物) founded by world-class immunologists in China. It specializes in the discovery and development of innovative biologics in the therapeutic areas of immune-oncology and autoimmune disease for global markets with a focus on China. The company’s current innovative pipeline includes 5 monoclonal antibodies at the preclinical stage and several clinical assets, such as olamkicept, in partnership with global pharma and biotech companies. I-MAB’s ongoing discovery is focused on developing novel bi-functional and bi-specific antibodies.

 

 

 

 

 
For News Release background on Ferring Pharmaceuticals click here
 
Media Contact Details
CONTACTS : Ferring Pharmaceuticals Lindsey Rodger Tel. +41 (0) 58 451 40 23 lindsey.rodger@ferring.com or IMAB Taylor Guo, PhD Tel: +86 138 183 78490 taylor.b.guo@3rdventure.com
 
 
Submit your press release
More News from Ferring Pharmaceuticals

10/04/2017 6:15PM

Ferring Announces Exclusive Agreement with Alrise Biosystems for the Development of an Injectable, Controlled-Release Peptide

Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with exclusive option rights for Ferring to leverage Alrise’s ImSus® Technology ...

07/04/2017 10:10AM

Ferring Highlights Progress on Social and Environmental Goals in Corporate Social Responsibility (CSR) Review 2015-2016

Ferring Pharmaceuticals releases its second Corporate Social Responsibility (CSR) review, highlighting progress on social and environmental goals in 2015 and 2016 across four key pillars for focus and activity: People, ...

03/04/2017 8:10PM

Ferring Appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer

Ferring Pharmaceuticals announced today that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer, effective 1st July 2017.   Moorhead succeeds Peter Wilden, who joined ...

Similar News

27/04/2017 9:45PM Document

Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; Board of Directors Recommends 2:1 Bonus Shares

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, announced today its consolidated financial results for the fourth quarter and full year FY17.

No Image

27/04/2017 7:20PM Image Youtube Script

Microfinance Organization Grameen Koota Receives ISC-FICCI 2017 Sanitation Award

Microfinance Organization Grameen Koota has received the ISC-FICCI 2017 Award for Best Financial Accessibility for Sanitation.